vs
Columbia Financial, Inc.（CLBK）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Columbia Financial, Inc.的1.8倍（$127.1M vs $68.8M），Columbia Financial, Inc.同比增速更快（29.7% vs 17.1%），Columbia Financial, Inc.自由现金流更多（$58.6M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 17.7%）
哥伦比亚金融公司（CLBK）是一家美国多元化金融服务及银行控股企业，提供财富管理、资产管理、保险、年金、遗产规划在内的全方位金融规划产品与服务，满足客户不同阶段的财务规划需求。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CLBK vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.8倍
$68.8M
营收增速更快
CLBK
高出12.6%
17.1%
自由现金流更多
CLBK
多$85.3M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
17.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $68.8M | $127.1M |
| 净利润 | $15.7M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 28.6% | -54.6% |
| 净利率 | 22.8% | — |
| 营收同比 | 29.7% | 17.1% |
| 净利润同比 | 173.9% | — |
| 每股收益（稀释后） | $0.15 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLBKZLAB
| Q4 25 | $68.8M | $127.1M | ||
| Q3 25 | $67.3M | $115.4M | ||
| Q2 25 | $63.9M | $109.1M | ||
| Q1 25 | $58.8M | $105.7M | ||
| Q4 24 | $46.4M | $108.5M | ||
| Q3 24 | $54.3M | $101.8M | ||
| Q2 24 | $53.3M | $100.1M | ||
| Q1 24 | $49.7M | $87.1M |
净利润CLBKZLAB
| Q4 25 | $15.7M | — | ||
| Q3 25 | $14.9M | $-36.0M | ||
| Q2 25 | $12.3M | $-40.7M | ||
| Q1 25 | $8.9M | $-48.4M | ||
| Q4 24 | $-21.2M | — | ||
| Q3 24 | $6.2M | $-41.7M | ||
| Q2 24 | $4.5M | $-80.3M | ||
| Q1 24 | $-1.2M | $-53.5M |
毛利率CLBKZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CLBKZLAB
| Q4 25 | 28.6% | -54.6% | ||
| Q3 25 | 29.5% | -42.3% | ||
| Q2 25 | 25.8% | -50.3% | ||
| Q1 25 | 20.4% | -53.3% | ||
| Q4 24 | -57.6% | -62.6% | ||
| Q3 24 | 13.5% | -66.6% | ||
| Q2 24 | 9.0% | -76.0% | ||
| Q1 24 | -2.6% | -80.7% |
净利率CLBKZLAB
| Q4 25 | 22.8% | — | ||
| Q3 25 | 22.1% | -31.2% | ||
| Q2 25 | 19.3% | -37.3% | ||
| Q1 25 | 15.1% | -45.8% | ||
| Q4 24 | -45.7% | — | ||
| Q3 24 | 11.4% | -40.9% | ||
| Q2 24 | 8.5% | -80.2% | ||
| Q1 24 | -2.3% | -61.4% |
每股收益（稀释后）CLBKZLAB
| Q4 25 | $0.15 | $-0.05 | ||
| Q3 25 | $0.15 | $-0.03 | ||
| Q2 25 | $0.12 | $-0.04 | ||
| Q1 25 | $0.09 | $-0.04 | ||
| Q4 24 | $-0.20 | $-0.09 | ||
| Q3 24 | $0.06 | $-0.04 | ||
| Q2 24 | $0.04 | $-0.08 | ||
| Q1 24 | $-0.01 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $340.8M | $689.6M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $1.2B | $715.5M |
| 总资产 | $11.0B | $1.2B |
| 负债/权益比越低杠杆越低 | 1.02× | — |
8季度趋势，按日历期对齐
现金及短期投资CLBKZLAB
| Q4 25 | $340.8M | $689.6M | ||
| Q3 25 | $253.4M | $717.2M | ||
| Q2 25 | $248.2M | $732.2M | ||
| Q1 25 | $256.1M | $757.3M | ||
| Q4 24 | $289.2M | $779.7M | ||
| Q3 24 | $283.5M | $616.1M | ||
| Q2 24 | $391.1M | $630.0M | ||
| Q1 24 | $373.5M | $650.8M |
总债务CLBKZLAB
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.5B | — |
股东权益CLBKZLAB
| Q4 25 | $1.2B | $715.5M | ||
| Q3 25 | $1.1B | $759.9M | ||
| Q2 25 | $1.1B | $791.7M | ||
| Q1 25 | $1.1B | $810.8M | ||
| Q4 24 | $1.1B | $840.9M | ||
| Q3 24 | $1.1B | $667.7M | ||
| Q2 24 | $1.0B | $704.2M | ||
| Q1 24 | $1.0B | $762.2M |
总资产CLBKZLAB
| Q4 25 | $11.0B | $1.2B | ||
| Q3 25 | $10.9B | $1.2B | ||
| Q2 25 | $10.7B | $1.2B | ||
| Q1 25 | $10.6B | $1.2B | ||
| Q4 24 | $10.5B | $1.2B | ||
| Q3 24 | $10.7B | $985.3M | ||
| Q2 24 | $10.8B | $987.4M | ||
| Q1 24 | $10.6B | $988.4M |
负债/权益比CLBKZLAB
| Q4 25 | 1.02× | — | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.01× | — | ||
| Q4 24 | 1.00× | — | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.61× | — | ||
| Q1 24 | 1.47× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $68.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $58.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | 85.1% | -21.0% |
| 资本支出强度资本支出/营收 | 14.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.36× | — |
| 过去12个月自由现金流最近4个季度 | $95.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CLBKZLAB
| Q4 25 | $68.4M | $-26.0M | ||
| Q3 25 | $31.0M | $-32.0M | ||
| Q2 25 | $14.6M | $-31.0M | ||
| Q1 25 | $-1.6M | $-61.7M | ||
| Q4 24 | $33.3M | $-55.8M | ||
| Q3 24 | $-28.3M | $-26.8M | ||
| Q2 24 | $18.6M | $-42.2M | ||
| Q1 24 | $14.1M | $-90.1M |
自由现金流CLBKZLAB
| Q4 25 | $58.6M | $-26.7M | ||
| Q3 25 | $28.1M | $-35.0M | ||
| Q2 25 | $12.9M | $-33.9M | ||
| Q1 25 | $-4.5M | $-63.2M | ||
| Q4 24 | $25.9M | $-58.4M | ||
| Q3 24 | $-31.1M | $-28.2M | ||
| Q2 24 | $17.2M | $-42.9M | ||
| Q1 24 | $12.5M | $-91.1M |
自由现金流率CLBKZLAB
| Q4 25 | 85.1% | -21.0% | ||
| Q3 25 | 41.8% | -30.4% | ||
| Q2 25 | 20.2% | -31.1% | ||
| Q1 25 | -7.6% | -59.9% | ||
| Q4 24 | 55.7% | -53.8% | ||
| Q3 24 | -57.3% | -27.7% | ||
| Q2 24 | 32.3% | -42.9% | ||
| Q1 24 | 25.1% | -104.5% |
资本支出强度CLBKZLAB
| Q4 25 | 14.3% | 0.5% | ||
| Q3 25 | 4.2% | 2.6% | ||
| Q2 25 | 2.7% | 2.6% | ||
| Q1 25 | 4.9% | 1.5% | ||
| Q4 24 | 16.0% | 2.4% | ||
| Q3 24 | 5.1% | 1.3% | ||
| Q2 24 | 2.6% | 0.7% | ||
| Q1 24 | 3.4% | 1.1% |
现金转化率CLBKZLAB
| Q4 25 | 4.36× | — | ||
| Q3 25 | 2.08× | — | ||
| Q2 25 | 1.19× | — | ||
| Q1 25 | -0.18× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -4.57× | — | ||
| Q2 24 | 4.09× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLBK
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
